Cumberland Pharmaceuticals (CPIX) Cash & Equivalents (2016 - 2025)
Cumberland Pharmaceuticals (CPIX) has disclosed Cash & Equivalents for 16 consecutive years, with $11.4 million as the latest value for Q4 2025.
- Quarterly Cash & Equivalents fell 36.29% to $11.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Dec 2025, down 36.29% year-over-year, with the annual reading at $11.4 million for FY2025, 36.29% down from the prior year.
- Cash & Equivalents hit $11.4 million in Q4 2025 for Cumberland Pharmaceuticals, down from $15.2 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $27.0 million in Q4 2021 to a low of $11.4 million in Q4 2025.
- Historically, Cash & Equivalents has averaged $18.9 million across 5 years, with a median of $18.2 million in 2022.
- Biggest five-year swings in Cash & Equivalents: rose 13.2% in 2024 and later crashed 36.29% in 2025.
- Year by year, Cash & Equivalents stood at $27.0 million in 2021, then fell by 26.93% to $19.8 million in 2022, then fell by 7.27% to $18.3 million in 2023, then dropped by 1.95% to $18.0 million in 2024, then tumbled by 36.29% to $11.4 million in 2025.
- Business Quant data shows Cash & Equivalents for CPIX at $11.4 million in Q4 2025, $15.2 million in Q3 2025, and $16.1 million in Q2 2025.